Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Zrinka Rajić Džolić is active.

Publication


Featured researches published by Zrinka Rajić Džolić.


Medicinal Chemistry Research | 2016

Design, synthesis, and cytostatic activity of novel pyrazine sorafenib analogs

Zrinka Rajić Džolić; Ivana Perković; Sandra Kraljević Pavelić; Mirela Sedić; Nataša Ilić; Dominique Schols; Branka Zorc

The current study is focused on a series of sorafenib analogs as potential antitumor agents. We have designed and synthesized nine novel pyrazine analogs 6a–i differing in amide and/or urea regions. Two alternative strategies for the preparation of title compounds were applied. The first strategy involved ether formation between 4-hydroxyphenyl urea 3 and 5-chloro-pyrazine-2-carboxamides 4. In the second strategy, ether functionality was introduced in the molecule before urea moiety and included preparation of 5-(4-aminophenoxy)-N-alkylpyrazine-2-carboxamides 5 and their reaction with 4-chloro-3-(fluoromethyl)phenyl isocyanate. Cytostatic activity of the title compounds was evaluated in vitro against a panel of cancer cell lines. Most of the tested compounds showed strong antiproliferative activity in the low micromolar range. 5-/4-[3-(4-chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy/-pyrazine-2-carboxylic acid (4-chloro-3-trifluoromethylphenyl)-amide (6g) was the most active compound (IC50 0.9–7.5 μM) and showed comparable or stronger activity than sorafenib, but also similar cytotoxicity to normal human fibroblast cells. Two compounds, namely, 5-/4-[3-(4-bromophenyl)-ureido]-phenyloxy/-pyrazine-2-carboxylic acid cyclopentylamide (6c) and 5-/4-[3-(4-chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy/-pyrazine-2-carboxylic acid cyclopentylamide (6h), exerted cytostatic activities that surpassed the effects observed with sorafenib in three cancer cell lines (HepG2, HeLa, A549, IC50 0.6–0.9 μM). Similar to sorafenib, compound 6h proved to be cytotoxic to normal human fibroblast cells, whereas compound 6c did not diminish proliferative capacity of these cells and could be regarded as the most promising derivative. Additional biological studies on the c-Raf activity using Western blot method revealed that antiproliferative activity of 6h could be at least partially attributed to its inhibitory effect on c-Raf activation similar to sorafenib. In contrast, 6c did not inhibit the activity of c-Raf, which implies that other cell signaling pathways govern its antiproliferative effects. Taking into account structural differences between compounds 6c and 6h, it is plausible to believe that the substituent in urea part of the molecule is essential for the interaction with c-Raf.


Acta Pharmaceutica | 2013

A convenient synthesis of new NSAID esters containing amino acid, urea and amide moieties.

Ivana Perković; Zrinka Rajić Džolić; Branka Zorc

Abstract A convenient synthetic method for the preparation of novel NSAID twin esters 6a-i containing amino acid residue, urea and amide moieties has been developed. The synthetic pathway applied for the preparation of target compounds and key intermediates 1-benzotriazolecarboxylic acid chloride (1), NSAID benzotriazolides 2a-c and N-(1-benzotriazolecarbonyl)-amino acids 3a-d involved benzotriazole as a synthetic auxiliary. The final preparation step of esters 6a-i included the solvent-free reaction of compounds 2a-c with amino acid derivatives 5a-g, bearing two hydroxyl groups, one at each terminal, beside urea and amide functionalities.


Croatica Chemica Acta | 2012

Benzotriazole as a Synthetic Auxiliary

Branka Zorc; Zrinka Rajić Džolić; Ivan Butula


Knjiga sažetaka FARMEBS 2018 | 2018

Dizajniranje i sinteza derivata klorokina kao potencijalnih Michaelovih akceptora

Barbara Rubinić; Maja Beus; Zrinka Rajić Džolić; Branka Zorc


Knjiga sažetaka | 2018

Cytostatic activity of novel primaquine-vorinostat hybrid drugs

Zvonimir Mlinarić; Maja Beus; Maja Antunović; Inga Marijanović; Zrinka Rajić Džolić; Branka Zorc


Farmaceutski glasnik : glasilo Hrvatskog farmaceutskog društva | 2018

Prenamjena lijekova kao strategija u razvoju novih lijekova

Filip Kozlina; Zvonimir Mlinarić; Zrinka Rajić Džolić


VII EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry | 2017

Design and synthesis of sahaquines, potential dual-acting antimalarials

Zrinka Rajić Džolić; Maja Beus; Zvonimir Mlinarić; Branka Zorc


Knjiga sažetaka | 2017

Dizajn i sinteza sahakina, potencijalnih antimalarika dvojnog djelovanja

Maja Beus; Zvonimir Mlinarić; Zrinka Rajić Džolić; Branka Zorc


Farmaceutski glasnik : glasilo Hrvatskog farmaceutskog društva | 2017

10. međunarodna konferencija o farmaceutskoj kemiji (JMMC 2017), Srebreno, 25.–28. lipnja 2017.

Ivana Perković; Maja Beus; Kristina Pavić; Zrinka Rajić Džolić; Branka Zorc


Farmaceutski glasnik : glasilo Hrvatskog farmaceutskog društva | 2017

Razlike u djelovanju lijekova uvjetovane spolom

Zrinka Rajić Džolić; Ivana Perković

Collaboration


Dive into the Zrinka Rajić Džolić's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dominique Schols

Rega Institute for Medical Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge